Peginterferon Alfa-2a (Pegasys) Does Not Alter the Pharmacokinetics of Methadone
In the US, injection drug use is arguably the highest risk factor for acquiring hepatitis C virus (HCV) infection. Injection drug users in recovery in the US increasingly are seeking access to combination therapy with peginterferon alfa plus ribavirin for treatment of both hepatitis C monoinfection and HIV-HCV coinfection. With so many methadone users in this patient population, it is imperative to examine the pharmacokinetics of methadone in conjunction with that of peginterferon.
The primary aim of the current study was to quantify the pharmacokinetics of methadone and the pharmacokinetics and pharmacodynamics of peginterferon alfa-2a (40 kd) [Pegasys] in patients with chronic hepatitis C undergoing methadone maintenance therapy.
Adults with chronic hepatitis C who had been receiving a consistent methadone maintenance regimen for at least 3 months were eligible for this open-label, multicenter, nonrandomized drug interaction study.
All patients received standard dose of 180 microgram subcutaneous peginterferon alfa-2a once weekly for 4 weeks and continued their methadone regimen. Serial blood samples were collected at baseline and immediately before and for up to 168 hours after study drug administration for the purposes of quantifying methadone and peginterferon alfa-2a serum concentrations.
The study was sponsored by Roche, Nutley, NJ.
M Sulkowski and others. Peginterferon alfa-2a does not alter the pharmacokinetics
of methadone in patients with chronic hepatitis C undergoing methadone
maintenance therapy. Clinical Pharmacology and Therapeutics 77(3): 214-224.
|Print this page Previous Page|
is hepatitis? | Our
Mission | Who's
Involved | Hepatitis
C News | Upcoming
Events | Brochures
HCV Awareness Items | Related Links | From the CEO | To Whom It May Concern |
Bulletins | Message Board | Webrings & Awards | Contact Information
|Copyright © Hepatitis C Association Inc. All rights reserved.|